Vanguard Portfolio Management
LBRX

Vanguard Portfolio Management’s LB Pharmaceuticals LBRX Stock Holding History

Vanguard Portfolio Management’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.94M Buy
152,162
+39,665
+35% +$1.17M ﹤0.01% 2445
2026
Q1 		$2.77M Buy
+112,497
New +$2.59M ﹤0.01% 2506

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Portfolio Management's LBRX Position: Q2 2026 in Review

Vanguard Portfolio Management increased its LB Pharmaceuticals (LBRX) stake by 35% in Q2 2026, buying an estimated $1.17M and bringing the position to 152,162 shares worth $4.94M. The position accounts for ﹤0.01% of the portfolio, ranked #2445.

Vanguard Portfolio Management first reported a position in LBRX in Q1 2026 and has held it in 2 quarters since. 114 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

  • Vanguard Portfolio Management held 152,162 shares of LB Pharmaceuticals worth $4.94M as of Q2 2026.
  • Vanguard Portfolio Management bought 39,665 LB Pharmaceuticals shares in Q2 2026, an estimated $1.17M.
  • LB Pharmaceuticals made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2445 holding.
  • Vanguard Portfolio Management first reported a position in LB Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 114 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.